{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+the+Breast&page=26",
    "query": {
      "condition": "Malignant Tumor of the Breast",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 618,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+the+Breast&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+the+Breast&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T03:21:41.301Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02898207",
      "title": "Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic High Grade Fallopian Tube Serous Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Primary Peritoneal Serous Adenocarcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent High Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent High Grade Ovarian Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Triple-Negative Breast Carcinoma",
        "Refractory Fallopian Tube Serous Adenocarcinoma",
        "Refractory Ovarian Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Serous Adenocarcinoma",
        "Refractory Triple-Negative Breast Carcinoma",
        "Unresectable High Grade Fallopian Tube Serous Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Primary Peritoneal Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Onalespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2017-05-19",
      "completion_date": "2022-01-14",
      "has_results": true,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02898207"
    },
    {
      "nct_id": "NCT03157128",
      "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Medullary Thyroid Cancer",
        "Colon Cancer",
        "Any Solid Tumor"
      ],
      "interventions": [
        {
          "name": "LOXO-292",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 857,
      "start_date": "2017-05-02",
      "completion_date": "2027-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 41,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03157128"
    },
    {
      "nct_id": "NCT02204098",
      "title": "Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Carcinoma",
        "Malignant Neoplasm of Breast"
      ],
      "interventions": [
        {
          "name": "Mammaglobin-A DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Optional biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2015-01-07",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204098"
    },
    {
      "nct_id": "NCT00802945",
      "title": "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2008-10",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2018-07-09",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Rancho Mirage, California • Stockton, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802945"
    },
    {
      "nct_id": "NCT07807345",
      "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head & Neck Squamous Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Endometrial Cancer",
        "Urothelial Carcinoma (UC)",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "STRO-006",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 285,
      "start_date": "2026-09-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Orlando, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Irving",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07807345"
    },
    {
      "nct_id": "NCT02175628",
      "title": "Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Signs and Symptoms"
      ],
      "interventions": [
        {
          "name": "Acoustic Angiography",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2014-06",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-05",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175628"
    },
    {
      "nct_id": "NCT06518057",
      "title": "Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Breast Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Leptomeninges",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Proton Beam Craniospinal Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Volume Modulated Arc Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Hippocampal-Avoidance Craniospinal Irradiation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2025-03-03",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06518057"
    },
    {
      "nct_id": "NCT02223052",
      "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Neoplasms",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Lymphoma",
        "Lymphoma",
        "Multiple Myeloma",
        "Acute Myeloid Leukemia",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Neoplasms",
        "Melanoma",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Glioblastoma Multiforme",
        "Osteosarcoma",
        "Sarcoma",
        "Thyroid Cancer",
        "Genitourinary"
      ],
      "interventions": [
        {
          "name": "CC-486",
          "type": "DRUG"
        },
        {
          "name": "Vidaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-10-27",
      "completion_date": "2018-12-18",
      "has_results": false,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02223052"
    },
    {
      "nct_id": "NCT04639245",
      "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PD1 Inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-07-19",
      "completion_date": "2022-08-16",
      "has_results": true,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639245"
    },
    {
      "nct_id": "NCT03428802",
      "title": "Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "Locally Advanced Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "POLD1 Gene Mutation",
        "POLE Gene Mutation",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Ovarian Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2018-03-08",
      "completion_date": "2027-09-21",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-15T03:21:41.301Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • New York, New York",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03428802"
    }
  ]
}